Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Fig. 6

MSA-2 combined with YM101 therapy altered the TME and promoted immunity-associated gene expression in B16 model. a–h Quantification of CD8+ T cell, Ki67+ CD8+ T cell, Perforin+ CD8+ T cell, IFN-γ+ CD8+ T cell, Granzyme-B+ CD8+ T cell, CD69+ CD8+ T cell, NK cell, DC. (i) The heatmap shows the differentially expressed genes among four groups. The levels of immune-killing genes including Prf1, Tnf, Gzma, and Gzmb were quantitatively analyzed. j–m GO enrichment analysis exploring biological processes significantly enriched in MSA-2 combined with YM101 group. n–s The scores of immune signatures. The heatmaps presenting the scaled expression level of genes constituting immune signatures. *p < 0.05 means the significant difference compared to MSA-2 combined with YM101

Back to article page